CClinicalTrials.gg
CompletedNCT06101212Updated Sep 19, 2024

Predictors of Quality of Life in Bipolar Disorder

An observational study in Bipolar Disorder, sponsored by Kubra TOHUMCU. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Kubra TOHUMCU · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
130
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study was planned to determine the predictive effects of impulsivity and coping skills on quality of life in patients with bipolar disorder. The sample of the study, which was carried out in a descriptive design, will consist of 80 patients who applied to Adıyaman Besni State Hospital Psychiatry Outpatient Clinic with a diagnosis of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-5 and who were in the euthymic period according to the doctor's control. It was planned to collect the data by applying the Personal Information Form prepared by the researchers, "Brief Quality of Life in Bipolar Disorder", "Barratt Impulsivity Scale -11 Short Form" and "Coping Attitudes Evaluation Scale". The data will be evaluated with descriptive statistics, Mann-Whitney U-test, Kruskal Wallis test, Pearson correlations and regression analyses using Statistical Package for the Social Sciences 22 software. Scale use and ethics committee permission were obtained from the responsible authors of the scales before the study.

Read the detailed description

Bipolar disorder is a chronic illness characterised by periods of illness and recovery, which can cause significant psychosocial impairment and disability. It affects more than 1% of the world population regardless of demographic characteristics such as ethnicity, nationality, socioeconomic status and is one of the leading causes of global disability. Bipolar disorder can cause serious cognitive and functional impairments and maintaining life with this disorder involves some difficulties for the individual. Functional impairments such as deterioration in family relationships, problems in work life and incompatibilities in social relationships negatively affect both the well-being and quality of life of the individual. Many individuals diagnosed with bipolar disorder have functional disorders that can cause low quality of life. Quality of life is recognised as an important outcome measure for the effectiveness of treatment of mental disorders. Compared to healthy individuals, the quality of life of patients with bipolar disorder is significantly impaired in both the euthymic and symptomatic periods. The ability to cope with difficulties is assumed to be a protective factor for quality of life. However, individuals diagnosed with bipolar disorder are exposed to more stressful events due to their illness and experience coping problems, including in the euthymic period. For these reasons, developing coping skills is among the targets in the treatment process of bipolar disorder. The stress coping strategies of these individuals may even affect the risk of suicide. Bipolar disorder is a serious illness that causes increased mortality, including death by suicide. Approximately 10-20% of these individuals end their lives and approximately one third of these individuals attempt suicide at least once.

Patients with bipolar disorder and previous suicide attempts have a worse quality of life. One of the most important factors associated with suicide and morbidity in bipolar disorder is impulsivity. Impulsivity, which can be defined as a predisposition to unplanned reactions to internal and external stimuli regardless of negative consequences and the absence of behavioural inhibition, is one of the clinical features of bipolar disorder. Although it is more common during manic episode, it can also be found in other mood phases. Bipolar disorder is characterised by high impulsivity even during recovery periods. Increased impulsivity is not only associated with suicide attempts but may also lead to functional impairment. Impulsive behaviours may cause long-term negative consequences in bipolar disorder that may affect quality of life. In the literature, it has been revealed that high impulsivity is associated with poor quality of life.

In the light of this information, this study aimed to determine the predictive effects of impulsivity and coping skills on quality of life in patients with bipolar disorder.

METHOD Sample The descriptive study is planned to be conducted in Adıyaman Besni State Hospital between October 2023-February 2024. The population of the study will consist of individuals who applied to the Psychiatry Outpatient Clinic of Adıyaman Besni State Hospital on the dates of the study, who received outpatient treatment with the diagnosis of bipolar according to Diagnostic and Statistical Manual of Mental Disorders-5 and who were in the euthymic period according to the doctor's control. G* Power programme was used to calculate the sample size. The confidence interval α=0.05, the power of the test (1-β) 0.95, the effect size dz= 0.5 were calculated as a total of 54 people (presented in the appendix).

The data will be collected by researcher Kubra Tohumcu through face-to-face interview technique. The patients constituting the sample of the study will be directed to the researcher by the outpatient clinic doctor. The data were planned to be collected by applying the "Personal Information Form", "Brief Quality of Life in Bipolar Disorder Scale", "Barratt Impulsivity Scale -11 Short Form" and "Coping Attitudes Evaluation Scale" prepared by the researchers.

Individual Information Form: This form, organised by the researchers, included 17 questions to determine the demographic information of the participants.

Brief Quality of Life in Bipolar Disorder Scale: Developed in 2010 by Michalak and Murray, the Turkish validity and reliability study of the scale was conducted by Gümüş et al. It is a 5-point Likert-type scale (1=Strongly Disagree, 5=Strongly Agree) consisting of a total of 7 items. The total score range that can be obtained from the scale varies between 12-60. Higher scores obtained from the scale indicate a better quality of life. Cronbach Alpha internal consistency coefficient was reported as .86.

Barratt Impulsivity Scale -11 Short Form: The scale consists of a total of 15 items and three subscales. These subscales are lack of planning, motor impulsivity and attention impulsivity. The items in the scale are evaluated using a 4-point Likert-type scale (1=rarely/never, 4=almost always/always). The high scores obtained from the scale indicate a high level of impulsivity. The Cronbach's alpha internal consistency coefficient for the entire scale adapted into Turkish was reported as .82, .80 for the failure to plan subscale, .70 for the motor impulsivity subscale, and .64 for attention impulsivity.

Coping Attitudes Rating Scale: The scale is a 4-point Likert-type scale (1=I Never Do This, 4=I Mostly Do This) consisting of 5 factors and 32 items. The score range to be obtained from the scale varies between 32-128, and the high score obtained from the scale indicates that the coping attitude level is high, while the low score obtained indicates that the coping attitude level is low. In the Turkish validity and reliability study of the scale, cronbach alpha value was .766.

Data analysis: The data of the study will be evaluated using descriptive statistical methods (frequency, mean), t-test, one way Analysis of Variance, correlation and regression analyses in Statistical Package for the Social Sciences 22 package programme.

02

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Bipolar Disorder
  • Quality of life
  • Impulsivity
  • Coping attitudes
03

In context

Bipolar Disorder

1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.

This study's enrollment of 130 is below the median of 160 across 329 observational studies indexed under Bipolar Disorder.

Browse Bipolar Disorder studies →

Lead sponsor

Kubra TOHUMCU is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The descriptive study is planned to be conducted in Adıyaman Besni State Hospital between October 2023-February 2024. The population of the study will consist of individuals who applied to the Psychiatry Outpatient Clinic of Adıyaman Besni State Hospital on the dates of the study, who received outpatient treatment with the diagnosis of bipolar according to Diagnostic and Statistical Manual of Mental Disorders-5 and who were in the euthymic period according to the doctor's control. G* Power programme was used to calculate the sample size. The confidence interval α=0.05, the power of the test (1-β) 0.95, the effect size dz= 0.5 were calculated as a total of 54 people (presented in the appendix).

Inclusion criteria

  • Receiving outpatient treatment with a diagnosis of Bipolar Disorder according to DSM-5
  • Being in euthymic mood according to the doctor's control at the time of the interview
  • Having no problem in understanding and speaking Turkish
  • Being in the 18-65 age group

Exclusion criteria

Exclusion Criteria:

  • Presence of serious sensory and cognitive impairment that would prevent answering the questionnaire
  • Refusing to participate in the study after being informed
  • Having another psychiatric diagnosis in addition to the diagnosis of bipolar disorder
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
130 participants (actual)
Patient registry
No

Interventions

  • Othersurvey

    After obtaining the informed consent form, a 10-15 minute questionnaire will be applied to the patients included in the study.

06

What researchers measure

Primary outcomes

  1. The Predictive Effect of Impulsivity on Quality of Life in Patients with Bipolar Disorder

    The effect of impulsivity level on quality of life in bipolar disorder patients. It was planned to collect the data by applying the "Personal Information Form", "Quality of Life in Bipolar Disorder Scale Short Form", "Barratt Impulsivity Scale -11 Short Form" and "Coping Attitudes Assessment Scale" prepared by the researchers. Barratt Impulsivity Scale minimum score=15 and maximum score=60. High scores indicate high impulsivity level of individuals. The results will be evaluated in line with the data obtained.

    Time frame: 15 October 2023-1 February 2024

Secondary outcomes

  1. The Predictive Effect of Coping Skills on Quality of Life in Patients with Bipolar Disorder

    The effect of coping skill level on quality of life in patients with bipolar disorder. It was planned to collect the data by applying the "Personal Information Form", "Quality of Life in Bipolar Disorder Scale Short Form", "Barratt Impulsivity Scale -11 Short Form" and "Coping Attitudes Assessment Scale" prepared by the researchers. The minimum score of the Coping Attitudes Assessment Scale=32 and the maximum score=128. High scores indicate that the coping attitude level of individuals is increased.

    Time frame: 15 October 2023-1 February 2024

07

Study locations

1 site
  • Besni State Hospital
    Besni, Adıyaman 02000, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06101212
Lead sponsor
Kubra TOHUMCU
Responsible party
Kubra TOHUMCU (principal investigator, University of Gaziantep) — Sponsor-investigator
First posted
Oct 26, 2023
Start date
Nov 15, 2023
Primary completion
Aug 10, 2024
Completion
Sep 5, 2024
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion